Medical Equipment

Oncology Biomarkers Market to Reach $29.39 Billion by 2029, Growing at a CAGR of 14.2%

November 17, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Oncology Biomarkers Industry In 2025?

The oncology biomarkers market has seen a swift expansion recently, projected to increase its value from $15.3 billion in 2024 to $17.3 billion in 2025, reflecting a compound annual growth rate of 13.0%; this upswing during the past period stems from several factors, notably the uptake of these biomarkers in developing nations, ongoing precision medicine efforts, advancements in diagnostic technologies, crucial support for pharmaceutical research and development, and a higher prevalence of cancer cases overall.

Anticipation points toward substantial expansion in the oncology biomarkers market over the forthcoming years, with its valuation projected to reach $29.39 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.2%. This upward trajectory throughout the projection timeframe is fueled by several key factors, such as the incorporation of next-generation sequencing (NGS), the broadening scope of biomarker informatics, an increasing emphasis on predictive pharmacogenomics, swift advancements in exosome-based biomarkers, and the broader uptake of spatial transcriptomics. Key developments shaping this market during the forecast era encompass efforts toward standardization and quality assurance protocols, a discernible pivot toward functional biomass, the growing significance of biomarkers within clinical trials, augmented utilization in immunotherapy contexts, and the implementation of real-time monitoring for assessing treatment efficacy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Oncology Biomarkers Industry?

Anticipation of an increase in cancer occurrences is forecasted to stimulate the expansion of the market for oncology biomarkers in the forthcoming period. Cancer is characterized by the runaway proliferation of specific bodily cells that subsequently infiltrate surrounding tissues throughout the physique. These oncological markers furnish deeper insights into the specific cancer type by examining constituents such as genes, proteins, and alternative substances present within an individual. To illustrate, data from the National Library of Medicine, a United States governmental organization, indicated in January 2024 that the United States is projected to see 2,001,140 new cancer diagnoses alongside 611,720 fatalities associated with the disease in the year 2024. Furthermore, an annual uptick of between 1% and 2% in the incidence rates for cervical cancer in the 30 to 44 age bracket and colorectal cancer among those younger than 55 has been observed in younger demographics. Consequently, this escalating prevalence of cancer is set to serve as a key impetus for the growth of the oncology biomarker sector.

How Is The Oncology Biomarkers Market Classified Into Different Segments?

The oncology biomarkersmarket covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Are The Major Trends Driving The Growth Of The Oncology Biomarkers Market?

A significant current in the oncology biomarker arena involves the embrace of novel and sophisticated technological solutions, with key industry players actively rolling out fresh, cutting-edge approaches to fortify their competitive standing within this market. As an illustration, consider the 2022 introduction by OncoDNA, a Belgian firm specializing in precision oncology, of OncoDEEP, a distinctive assay facilitating extensive biomarker evaluation within laboratory settings. This OncoDEEP system leverages Next-generation sequencing methodologies alongside software residing in the cloud, thereby equipping labs with the capacity to execute broad-panel sequencing, ascertain the complete molecular profile of a neoplasm, process the initial datasets, and utilize comprehensive quality assurance mechanisms.

Who Are The Prominent Global Companies Shaping The Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

How Do Regional Market Performances Compare Within The Oncology Biomarkers Industry?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Oncology Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2025, By The Business Research Company

Immuno Oncology Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Interventional Oncology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/interventional-oncology-devices-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795